Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FE 202158 in vasodilatory hypotension in early septic shock
2009-010798-19Phase 2Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jul 2009
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in septic shock and Vasodilatory shock comparing FE 202158 infusion with Placebo infusion (2 arms). Primary endpoints: Proof-of-concept for specific V1a agonism and Pharmacokinetics of FE 202158. Started Jul 2009; status: completed.
02
Drugs
selepressin
03
Conditions
septic shockVasodilatory shock
Beyond the preview
Go deeper on 2009-010798-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010798-19.